EP0737314A4 - Nouvelles utilisations de produits de recombinaison de recepteurs de gal4 - Google Patents

Nouvelles utilisations de produits de recombinaison de recepteurs de gal4

Info

Publication number
EP0737314A4
EP0737314A4 EP95905946A EP95905946A EP0737314A4 EP 0737314 A4 EP0737314 A4 EP 0737314A4 EP 95905946 A EP95905946 A EP 95905946A EP 95905946 A EP95905946 A EP 95905946A EP 0737314 A4 EP0737314 A4 EP 0737314A4
Authority
EP
European Patent Office
Prior art keywords
gal4
novel uses
receptor constructs
constructs
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP95905946A
Other languages
German (de)
English (en)
Other versions
EP0737314A1 (fr
Inventor
Ronald M Evans
Kazuhiko Umesono
Bruce Blumberg
Pundi N Rangarajan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Priority to EP96111192A priority Critical patent/EP0743520A3/fr
Publication of EP0737314A1 publication Critical patent/EP0737314A1/fr
Publication of EP0737314A4 publication Critical patent/EP0737314A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP95905946A 1993-12-30 1994-12-29 Nouvelles utilisations de produits de recombinaison de recepteurs de gal4 Ceased EP0737314A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96111192A EP0743520A3 (fr) 1993-12-30 1994-12-29 Utilisations nouvelles des structures de GAL4-récepteur

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17774093A 1993-12-30 1993-12-30
US177740 1993-12-30
PCT/US1994/014426 WO1995018380A1 (fr) 1993-12-30 1994-12-29 Nouvelles utilisations de produits de recombinaison de recepteurs de gal4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP96111192A Division EP0743520A3 (fr) 1993-12-30 1994-12-29 Utilisations nouvelles des structures de GAL4-récepteur

Publications (2)

Publication Number Publication Date
EP0737314A1 EP0737314A1 (fr) 1996-10-16
EP0737314A4 true EP0737314A4 (fr) 1999-11-03

Family

ID=22649809

Family Applications (2)

Application Number Title Priority Date Filing Date
EP95905946A Ceased EP0737314A4 (fr) 1993-12-30 1994-12-29 Nouvelles utilisations de produits de recombinaison de recepteurs de gal4
EP96111192A Withdrawn EP0743520A3 (fr) 1993-12-30 1994-12-29 Utilisations nouvelles des structures de GAL4-récepteur

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP96111192A Withdrawn EP0743520A3 (fr) 1993-12-30 1994-12-29 Utilisations nouvelles des structures de GAL4-récepteur

Country Status (5)

Country Link
EP (2) EP0737314A4 (fr)
JP (2) JPH09504111A (fr)
AU (2) AU1436695A (fr)
CA (2) CA2180271A1 (fr)
WO (1) WO1995018380A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737314A4 (fr) * 1993-12-30 1999-11-03 Salk Inst For Biological Studi Nouvelles utilisations de produits de recombinaison de recepteurs de gal4
US6770446B1 (en) 1994-06-14 2004-08-03 Wyeth Cell systems having specific interaction of peptide binding pairs
US5989808A (en) 1994-06-14 1999-11-23 American Cyanamid Company Identification of compounds affecting specific interaction of peptide binding pairs
EP0788353A1 (fr) 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Antagonistes de ppar gamma pour le traitement de l'obesite
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO1998048055A1 (fr) 1997-04-24 1998-10-29 Institut National De La Sante Et De La Recherche Medicale Procedes et compositions a utiliser dans la modulation de l'expression de genes de metalloproteinases matricielles
WO1999000491A1 (fr) 1997-06-27 1999-01-07 Ono Pharmaceutical Co., Ltd. Nouvel adn plasmidique contenant de l'adn de gene reporter et utilisation associee
EP1024193A4 (fr) * 1997-07-22 2004-12-15 Chugai Pharmaceutical Co Ltd Methode de criblage de genes utilisant les recepteurs nucleaires
CA2334545A1 (fr) 1998-06-12 1999-12-16 Ligand Pharmaceuticals Incorporated Traitement du cancer du sein resistant aux anti-oestrogenes avec des modulateurs de rxr
WO2000052153A2 (fr) * 1999-03-02 2000-09-08 Maxygen, Inc. Ligands delegues pour recepteur orphelins
ATE385421T1 (de) 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
WO2002097099A1 (fr) * 2001-05-29 2002-12-05 Valentis, Inc. Expression regulee de somatostatine
EP1465882B1 (fr) 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Modulateurs heterocycliques de recepteurs nucleaires
EP1388352A1 (fr) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Utilisation d'un agoniste de PPAR-alpha pour traiter l'obesité associée au traitement avec un agonist de PPAR-gamma dans des patients
EP1544307A1 (fr) * 2003-12-18 2005-06-22 AXXAM S.r.l. Recepteur chimerique LAC9 et ses utilisations
KR101363278B1 (ko) 2005-06-27 2014-02-21 엑셀리시스 페이턴트 컴퍼니 엘엘씨 이미다졸계 ｌｘｒ 변조제
GEP20135791B (en) 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
WO2013037482A1 (fr) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Agonistes du récepteur du farnésoïde x pour le traitement et la prévention du cancer
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016546A1 (fr) * 1991-03-19 1992-10-01 The Salk Institute For Biological Studies Compositions a element de reaction et dosages les utilisant
WO1993006215A1 (fr) * 1991-09-17 1993-04-01 The Salk Institute For Biological Studies Recepteurs de la superfamille des recepteurs d'hormones thyroidiennes/steroides
WO1993023431A1 (fr) * 1992-05-14 1993-11-25 Baylor College Of Medicine Recepteurs d'hormones steroides mutees, procede d'utilisation et commutateur moleculaire pour therapie genique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737314A4 (fr) * 1993-12-30 1999-11-03 Salk Inst For Biological Studi Nouvelles utilisations de produits de recombinaison de recepteurs de gal4

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016546A1 (fr) * 1991-03-19 1992-10-01 The Salk Institute For Biological Studies Compositions a element de reaction et dosages les utilisant
WO1993006215A1 (fr) * 1991-09-17 1993-04-01 The Salk Institute For Biological Studies Recepteurs de la superfamille des recepteurs d'hormones thyroidiennes/steroides
WO1993023431A1 (fr) * 1992-05-14 1993-11-25 Baylor College Of Medicine Recepteurs d'hormones steroides mutees, procede d'utilisation et commutateur moleculaire pour therapie genique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9518380A1 *

Also Published As

Publication number Publication date
JPH09275988A (ja) 1997-10-28
AU700646B2 (en) 1999-01-14
EP0743520A3 (fr) 1999-11-10
EP0737314A1 (fr) 1996-10-16
AU5837496A (en) 1996-10-03
JPH09504111A (ja) 1997-04-22
CA2182908A1 (fr) 1995-07-01
AU1436695A (en) 1995-07-17
WO1995018380A1 (fr) 1995-07-06
EP0743520A2 (fr) 1996-11-20
CA2180271A1 (fr) 1995-07-06

Similar Documents

Publication Publication Date Title
GB9302275D0 (en) Novel compounds
AP9400653A0 (en) Novel compounds
AU5837496A (en) Novel uses for GAL4-receptor constructs
HU9600805D0 (en) Polyazacycloalkanes as dichelants
GB9306460D0 (en) Novel compounds
GB9306183D0 (en) Novel compounds
GB9308963D0 (en) Novel compounds
GB9310485D0 (en) Novel compounds
GB9303825D0 (en) Novel compounds
ZA94961B (en) 15-oxasterols as hypocholesterolemics
GB9306235D0 (en) Novel compounds
GB9308178D0 (en) Novel compounds
GB9306182D0 (en) Novel compounds
IL111753A0 (en) Novel substituted thiosemicarbazonethiones
GB9307694D0 (en) Novel compounds
ZA935901B (en) Novel amidoalkyl- and imodoalkyl-piperazines
GB9311027D0 (en) Novel compounds
GB9311600D0 (en) Novel compounds
GB9303617D0 (en) Novel compounds
GB9303607D0 (en) Novel compounds
GB9309835D0 (en) Novel compounds
GB9301980D0 (en) Novel compounds
GB9310687D0 (en) Novel compounds
GB9309181D0 (en) Novel compounds
GB9304414D0 (en) Novel compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960508

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

XX Miscellaneous (additional remarks)

Free format text: TEILANMELDUNG 96111192.9 EINGEREICHT AM 11/07/96.

A4 Supplementary search report drawn up and despatched

Effective date: 19990920

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000308

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20040113